Method for Treating Ulcerative Colitis or Primary Sclerosing Cholangitis

2:

• The system according to claim 1, wherein the means comprises a substance that specifically binds to the anti-integrin αvβ6 antibody or the anti-integrin αvβ6 antibody-producing B cell.

3:

• The system according to claim 2, wherein the substance is a fragment or an entirety of integrin αvβ6 protein.

4:

• The system of claim 3, which comprises a column carrying a fragment or an entirety of integrin αvβ6 protein.

5:

• A solid carrier for the treatment of ulcerative colitis or primary sclerosing cholangitis, the solid carrier comprising a fragment or an entirety of integrin αvβ6 protein capable of specifically binding to an anti-integrin αvβ6 antibody or an anti-integrin αvβ6 antibody-producing B cell that produces the anti-integrin αvβ6 antibody, and thereby being capable of adsorbing the anti-integrin αvβ6 antibody or the anti-integrin αvβ6 antibody-producing B cell, wherein the anti-integrin αvβ6 antibody has activity competing with fibronectin for binding to integrin αvβ6 and is specifically produced in a subject suffering from ulcerative colitis or primary sclerosing cholangitis.

6:

• The solid carrier according to claim 5, wherein the anti-integrin αvβ6 antibody comprises a heavy chain CDR2 or CDR3 comprising any one amino acid sequence selected from RGD, RGRD, or RGSGD, and the fragment or entirety of integrin αvβ6 protein has a binding dissociation constant (KD value) of 100 nM or less for the anti-integrin αvβ6 antibody.

7:

• The solid carrier according to claim 5, wherein the integrin αvβ6 protein is immobilized at a weight equal to or greater than twice the weight of the antibody to be captured, or the fragment of integrin αvβ6 protein is immobilized at a weight equal to or greater than a value obtained by multiplying twice the weight of the antibody to be captured by a proportion of the molecular weight of the fragment to the molecular weight of the entirety of integrin αvβ6.

8:

• A column comprising the solid carrier according to claim 5.

9:

• The column according to claim 8, which comprises the solid carrier such that the weight of the integrin αvβ6 protein per column is at least twice the weight of the antibody to be captured, or the weight of the fragment of integrin αvβ6 protein per column is at least a value obtained by multiplying twice the weight of the antibody to be captured by a proportion of the molecular weight of the fragment to the molecular weight of the entirety of integrin αvβ6.

10:

• The column according to claim 8, which is used for apheresis.

11:

• A method for producing an animal model of primary sclerosing cholangitis, the method comprising immunizing a non-human animal with a fragment or an entirety of integrin αvβ6 protein.

12:

• A method for producing an animal model of primary sclerosing cholangitis, the method comprising knocking out an integrin β6 gene in a non-human animal.

13:

• A method for producing an animal model of an ulcerative colitis or primary sclerosing cholangitis, the method comprising administering to a non-human animal an anti-integrin αvβ6 antibody derived from a patient with ulcerative colitis or primary sclerosing cholangitis.

14:

• The method according to claim 13, wherein the antibody is a serum or a monoclonal antibody.

15:

• An animal model of ulcerative colitis having a symptom of ulcerative colitis.

16:

• An animal model of primary sclerosing cholangitis having a symptom of primary sclerosing cholangitis.

17:

• The animal model of primary sclerosing cholangitis according to claim 16, which is a knockout mouse lacking the function of integrin αvβ6.